Reasons To Own Regeneron In 2017; CS Sees 30% Upside
December 20, 2016 at 12:58 PM EST
It looks like 2017 will be a big year for Regeneron ( REGN ). Credit Suisse upgraded the stock a market perform to an outperform and sees the share price climbing 30% over the next year to $485. And a big part of that bullish argument revolves around the anticipated 2017 launch of the eczema drug Dupixent. Now awaiting FDA approval, the drug is widely expected to be the company’s next big blockbuster. But Credit Suisse analyst Alethia Young and her team of analysts see several other catalysts --more catalysts than risks -- ahead in 2017. In fact, she says there are five major events to watch for next year.